Balancing Clinical and Economic Considerations in Treatment Adoption
Panelists discuss how integrating clinical efficacy with cost-effectiveness ensures sustainable adoption of MASH therapies.
Expanding the Therapeutic Horizon in MASH
Panelists discuss how next-generation metabolic and hepatic agents are broadening treatment options and reshaping the MASH care landscape.
Evidence for GLP-1 Therapy in MASH
Panelists discuss how GLP-1 therapies show dual metabolic and hepatic benefits, redefining MASH management.
Recognizing Risk and the Broader Health Impact in MASH
Panelists discuss how recognizing high-risk patients and linking liver care with metabolic management can reduce both disease and economic impact.
Enhancing Early Detection and Diagnosis in MASH
Panelists discuss how structured, multidisciplinary screening efforts can catch MASH earlier and prevent progression.
Understanding the Metabolic–Hepatic Connection in MASH
Panelists discuss how metabolic dysfunction drives liver injury, highlighting early recognition of the obesity–MASH connection as key to prevention.
